



सत्यमेव जयते

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL
ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road New
Delhi - 110002 (Delhi) Phone No.:
91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/23/000116

To,

M/s George Clinical India Pvt. Ltd.,
Plot No. 5, Prestige Khoday Towers,
12th Floor Raj Bhavan Road,
Bengaluru (India) – 560001.

Sir,

With reference to your application No. GCT/CT04/FF/2023/39668 (GCT/116/23) dated 18/09/2023, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, **“A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy” Protocol no. 417-201-00012, Amendment 1, dated 14/Mar/2023 with a total of up-to 99 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (ii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (iii) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) the Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

- (vi) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- (ix) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (xi) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvi) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

- (xviii) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;
- (xix) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Central Licencing Authority
Stamp

FORM CT-06

(See rules 22,25,26,29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

1. The Central Licensing Authority hereby permits **M/s. George Clinical India Pvt Ltd., Plot No. 5, Prestige Khoday Towers, 12th Floor Raj Bhavan Road Bengaluru (India) – 560001** Telephone No.: **8049421400**, FAX: **8049421426** E-Mail : **INFOREGULATORY@GEORGECLINICAL.COM** to conduct clinical trial of the new drug or investigational new drug as per **Protocol no. 417-201-00012, Amendment 1, dated 14/Mar/2023** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date _____

(Dr. Rajeev Singh Raghuvanshi
Drugs Controller General (India)
Central Licensing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licensing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Sibeprenlimab (VIS649) Pre-filled 2 ml Syringes
Therapeutic class:	Humanized immunoglobulin G2 monoclonal antibody
Dosage form:	Pre-filled Syringes
Composition:	CE-SDS Reduced 90.0000 to 99.0000 % In House Specification Active CE-SDS NonReduced 80.0000 to 99.0000 % In House Specification Inactive SEC-HPLC 95.0000 to 99.0000 % In House Specification Individual Impurity Endotoxin 0.1000 to 0.2000 % In House Specification Total Impurity
Indications:	Immunoglobulin A Nephropathy

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	Department of Nephrology, Ground Floor, C-Block, Nehru Hospital, Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, Sector-12, 160012	Institute Ethics Committee, Research Block-B, 6 th Floor, Room No. 6006, PN Chuttani Block, PGIMER, Chandigarh, Sector-12, 160012	Dr. Raja Ramachandran
2.	Osmania General Hospital, Afzalgunj Hyderabad, India-500012	Institution Ethics Committee, Osmania Medical College, Koti Hyderabad, Telangana, India-500095 ECR/300/Inst/AP/2013/RR-19	Dr. Manisha Sahay
3.	Nizam's Institute of Medical Sciences, Panjagutta Rd, Panjagutta, Hyderabad, Telangana-500082, India	NIMS Institutional Ethics Committee, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad, Telangana-500082, India ECR/303/Inst/AP/2013/RR-19	Dr. D. Sreebhusan Raju
4.	Dept. of Nephrology, Govt. Medical College, Calicut, Kerala-673008, India	Institutional Ethics Committee, Room No. 1&2, lecture Theatre Complex, Govt. Medical College, Kozhikode-673008, India ECR/395/Inst/KL/2020	Dr.. Sreelatha Melemadathil
5.	Dept. of Nephrology, Christian Medical College Vellore Ranipet Campus, 6 th Floor A Block, Kilminnal Village, Ranipet District-632517	Institutional Review Board & The Ethics Committee, CMC Campus, Bagayam, Vellore-632002, Tamil nadu ECR/326/Inst/TN/2013/RR-19	Dr. Suceena Alexander
6.	Mazumdar Shaw Medical Center-a unit of Narayana Health No.258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru, Karnataka-560099, India	Narayana Health Medical Ethics Committee, No 258/A, Bommasandra Industrial Area, Anekal Taluk, Bangalore 560099 ECR/390/Inst/KA/2013/RR-19	Dr. Limesh M

File No. CT/116/23-DCG(I)

7.	Sir Ganga Ram Hospital, Old Rajinder Nagar, New Delhi-110060, India	Institutional Ethics Committee, Sir Ganga Ram Hospital, Old Rajinder Nagar, New Delhi-110060 ECR/20/Inst/DL/2013/RR-19	Dr. Anil Kumar Bhalla
8.	Government Medical College, Department of Nephrology, Super Speciality Building, Ulloor Road, Thiruvananthapuram, Kerala - 695011, India	Human Ethics committee, Department of Pharmacology, Govt Medical College, Thiruvananthapuram, Kerala - 695011, India ECR/370/Inst/Ker/2013/RR-20	Dr. Noble Gracious S.S
9.	Kasturba Medical college and Hospital, Udupi -Hebri Rd, Madhav Nagar, Manipal -576104, Karnataka, India	MAHE Ethics Committee, Mezzanine floor of Old KMC library Building, MAHE,Manipal-576104 ECR/191/Inst/KL/2013/RR-19	Dr. Ravindra Prabhu
10.	Sanjay Gandhi Post graduate institute of Medical Sciences, Raebareli road, Lucknow - 226014	Institutional Ethics Committee, Administrative block, Room no -205, Second Floor, SGPGIMS, LUCKNOW - 226014 ECR/16/Inst/UP/2013/RR-20	Dr. Narayan Prasad
11.	Jawaharlal Institute of Postgraduate Medical Education & Research, JIPMER Dhanvantari Nagar, Puducherry - 605006	Institutional Ethics committee Human Interventional Studies-JIPMER, Jawaharlal Institute of Postgraduate Medical Education & Research, JIPMER Dhanvantari Nagar, Puducherry -605006 ECR/16/Inst/UP/2013/RR-20	Dr. PriyamVada PS
12.	MS Ramaiah Medical College & Hospital, M S Ramaiah Nagar, MSRIT, Bengaluru, Karnataka-560054, India	Institutional Ethics Committee, M S Ramaih Medical College & Hospitals, MS Ramaiah Memorial Hospital, M S Ramaiah Nagar, MSRIT Post ,Bangalore-560054, Karnataka, India ECR/215/Inst/KA/2013/RR-22	Dr. Gurudev K. C
13.	KD Hospital, Vaishnodevi Circle, SG Highway, Ahmedabad, Gujarat - 382421, India	KD Hospital Institutional Ethics Committee, KD Hospital, Vaishnodevi Circle, SG Highway, Ahmedabad, Gujarat-382421 ECR/1294/Inst/GJ/2019	Dr. Jaykumar Patel

File No. CT/116/23-DCG(I)

14.	Muljibhai Patel Urological Hospital, Dr. Virendra Desai Road, Nadiad, Gujarat -387001, India	Institutional Ethics Committee Muljibhai Patel Society for Research in Nephro-Urology Ethics Committee, Jayaramdas Patel Academic Center, Muljibhai Patel Urological Hospital, Dr. Virendra Desai Road, Nadiad, Gujarat - 387001, India ECR/276/Muljibhai/Inst/GJ/2013/RR-19	Dr. Umapati Narasinha Hegde
15.	Government Stanley Medical College and Hospital, No. 1, Old Jail Rd, Chennai-600001, Tamil nadu, India	Institutional Ethics Committee, Stanley Medical College and Hospital, No. 1, Old Jail Rd, Chennai-600001, Tamil nadu, India	Dr. Edwin Fernando
16.	Mahatma Gandhi Mission, MGM Medical College and Hospital, N-6 Cidco, Aurangabad -431003, Maharashtra -India	Institutional Ethics Committee, Mahatma Gandhi Missions Ethics Committee for research on human Subjects, B wing 3rd Floor, Department Of Pharmacology Clinical trial Centre unit Number 602, Maharashtra 431003 ECR/581/Inst/MH/2014/RR-20	Dr. Sudhir Kulkarni
17.	Lifepoint Multispecialty Hospital, 145/1, Mumbai Bangalore Highway, near Sayaji Hotel, Wakad, Pune -411057, Maharashtra, India	LPR Ethics Committee, Lifepoint Multispecialty Hospital, 3 rd Floor, Clinical Research Department, 145/1, Mumbai Bangalore Highway, Near Hotel Sayaji, Wakad, Pune -411057, Maharashtra, India ECR/751/Inst/MH/2015/RR-21	Dr. Tarun Kumar Jeloka
